MX2009008561A - Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. - Google Patents

Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.

Info

Publication number
MX2009008561A
MX2009008561A MX2009008561A MX2009008561A MX2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A
Authority
MX
Mexico
Prior art keywords
growth hormone
cell proliferative
proliferative disorders
treating cell
hormone secretagogues
Prior art date
Application number
MX2009008561A
Other languages
English (en)
Spanish (es)
Inventor
Williams J Polvino
Original Assignee
Helsinn Therapeutics Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Therapeutics Us Inc filed Critical Helsinn Therapeutics Us Inc
Publication of MX2009008561A publication Critical patent/MX2009008561A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2009008561A 2007-02-13 2008-02-08 Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. MX2009008561A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90160907P 2007-02-13 2007-02-13
PCT/US2008/001748 WO2008100448A2 (en) 2007-02-13 2008-02-08 Method of treating cell proliferative disorders using growth hormone secretagogues

Publications (1)

Publication Number Publication Date
MX2009008561A true MX2009008561A (es) 2010-01-15

Family

ID=39690677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008561A MX2009008561A (es) 2007-02-13 2008-02-08 Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.

Country Status (12)

Country Link
US (1) US20080207640A1 (https=)
EP (1) EP2134341B1 (https=)
JP (1) JP2010518158A (https=)
KR (1) KR20090112720A (https=)
CN (1) CN101686966A (https=)
AU (1) AU2008216789A1 (https=)
CA (1) CA2677813A1 (https=)
EA (1) EA200970764A1 (https=)
IL (1) IL200367A0 (https=)
MX (1) MX2009008561A (https=)
TW (1) TWI450719B (https=)
WO (1) WO2008100448A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011105611A1 (ja) * 2010-02-26 2013-06-20 ラクオリア創薬株式会社 悪液質を治療するためのグレリン受容体作動物質
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
ES2925071T3 (es) 2013-02-08 2022-10-13 Gen Mills Inc Productos alimentarios reducidos en sodio
GEP20186939B (en) * 2014-09-04 2018-12-25 Healthcare Sa Helsinn Medical treatments based on anamorelin
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
BR112022002767A2 (pt) 2019-08-30 2022-05-10 Helsinn Healthcare Sa Métodos de fabricação de um comprimido de cloridrato de anamorelina, comprimidos e método para melhorar um ou mais sintomas de caquexia de câncer
IL293340A (en) 2019-12-02 2022-07-01 Storm Therapeutics Ltd Polyheterocyclic compounds as mettl3 inhibitors
WO2025104491A1 (en) 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU224345B1 (hu) * 1993-12-23 2005-08-29 Novo Nordisk A/S. Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
WO1997023508A1 (en) * 1995-12-22 1997-07-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998003473A1 (en) * 1996-07-22 1998-01-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6566334B1 (en) * 1997-02-06 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Short amphipathic peptides with activity against bacteria and intracellular pathogens
US6494563B2 (en) * 1997-12-25 2002-12-17 Canon Kabushiki Kaisha Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted
US6286927B1 (en) * 1997-12-25 2001-09-11 Canon Kabushiki Kaisha Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted
US6083908A (en) * 1998-01-16 2000-07-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US6919315B1 (en) * 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6566337B1 (en) * 1998-11-03 2003-05-20 Novo Nordisk A/S Compounds with growth hormone releasing properties
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
ATE446758T1 (de) * 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
JP2003535144A (ja) * 2000-06-07 2003-11-25 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 多能性造血幹細胞の流動を刺激するヒト成長ホルモン
JP2004532838A (ja) * 2001-03-02 2004-10-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモデュレーターとして有用な化合物及びそれを含む製薬組成物
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
KR20070010151A (ko) 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 c-반응성 단백질을감소시키는 방법
KR20090107088A (ko) * 2007-02-09 2009-10-12 트랜자임 파르마 인크 거대고리 그렐린 수용체 조절제 및 이의 사용 방법

Also Published As

Publication number Publication date
EP2134341B1 (en) 2015-06-17
JP2010518158A (ja) 2010-05-27
TWI450719B (zh) 2014-09-01
EP2134341A2 (en) 2009-12-23
IL200367A0 (en) 2010-04-29
CN101686966A (zh) 2010-03-31
CA2677813A1 (en) 2008-08-21
EP2134341A4 (en) 2011-08-17
AU2008216789A1 (en) 2008-08-21
US20080207640A1 (en) 2008-08-28
TW200914019A (en) 2009-04-01
KR20090112720A (ko) 2009-10-28
EA200970764A1 (ru) 2010-04-30
WO2008100448A2 (en) 2008-08-21
WO2008100448A3 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
MX2009008561A (es) Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MX2013012588A (es) Inhibidores de cinasa.
TN2012000248A1 (en) Novel spiropiperidine compounds
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX2022001863A (es) Metodos para tratar los tumores del estroma gastrointestinal.
IN2014KN00948A (https=)
JO2885B1 (en) Protein kinase inhibitors
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
WO2012082718A3 (en) 3-methanesulfonylpropionitrile for treating inflammation and pain
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
MX360030B (es) Metodos para tratar el trastorno bipolar.
WO2010149578A3 (en) Novel biphenyl and phenyl-pyridine amides
MX2012002387A (es) Aminas de triazol fusionadas como moduladores p2x7.
WO2012078757A3 (en) Combination for breast cancer therapy with hsp90 inhibitory compounds
MY191352A (en) Aldosterone synthase inhibitors
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
PH12019501566B1 (en) Amide compounds and use thereof
MX343165B (es) Agonistas del receptor 5-ht4 para el tratamiento de demencia.
MY156955A (en) Antifungal agents
WO2010039920A3 (en) Boldine compounds for promoting bone growth
WO2010002835A3 (en) Vinpocetine and eburnamonine derivatives for promoting bone growth

Legal Events

Date Code Title Description
FA Abandonment or withdrawal